INmune Bio (INMB) Scheduled to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB - Get Free Report) is set to release its earnings data after the market closes on Thursday, October 31st. Analysts expect INmune Bio to post earnings of ($0.49) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%. On average, analysts expect INmune Bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

INmune Bio Trading Up 3.8 %

NASDAQ INMB traded up $0.20 during trading hours on Friday, hitting $5.42. 495,993 shares of the company's stock traded hands, compared to its average volume of 158,558. INmune Bio has a 52 week low of $4.78 and a 52 week high of $14.74. The firm has a market capitalization of $107.22 million, a P/E ratio of -2.91 and a beta of 1.85. The business's fifty day moving average price is $5.74 and its two-hundred day moving average price is $7.98.

Analyst Ratings Changes

Several equities analysts recently weighed in on INMB shares. Scotiabank assumed coverage on INmune Bio in a research report on Thursday, August 22nd. They set a "sector outperform" rating and a $22.00 target price on the stock. Alliance Global Partners started coverage on shares of INmune Bio in a report on Monday. They set a "buy" rating and a $20.00 price target on the stock. Finally, Raymond James assumed coverage on shares of INmune Bio in a research note on Friday, September 27th. They issued an "outperform" rating and a $18.00 price objective for the company.

Insider Buying and Selling at INmune Bio

In related news, CFO David J. Moss acquired 7,690 shares of the company's stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, with a total value of $49,062.20. Following the acquisition, the chief financial officer now directly owns 1,275,869 shares of the company's stock, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In other INmune Bio news, CFO David J. Moss acquired 7,690 shares of the stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now directly owns 1,275,869 shares of the company's stock, valued at $8,140,044.22. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David J. Moss acquired 10,000 shares of the company's stock in a transaction on Monday, September 30th. The stock was acquired at an average cost of $5.29 per share, with a total value of $52,900.00. Following the completion of the purchase, the chief financial officer now directly owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 33,070 shares of company stock valued at $200,087 in the last three months. 35.20% of the stock is currently owned by corporate insiders.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.